216 related articles for article (PubMed ID: 34509095)
1. Canadian ROS proto-oncogene 1 study (CROS) for multi-institutional implementation of ROS1 testing in non-small cell lung cancer.
Cheung CC; Smith AC; Albadine R; Bigras G; Bojarski A; Couture C; Cutz JC; Huang WY; Ionescu D; Itani D; Izevbaye I; Karsan A; Kelly MM; Knoll J; Kwan K; Nasr MR; Qing G; Rashid-Kolvear F; Sekhon HS; Spatz A; Stockley T; Tran-Thanh D; Tucker T; Waghray R; Wang H; Xu Z; Yatabe Y; Torlakovic EE; Tsao MS
Lung Cancer; 2021 Oct; 160():127-135. PubMed ID: 34509095
[TBL] [Abstract][Full Text] [Related]
2. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
Mescam-Mancini L; Lantuéjoul S; Moro-Sibilot D; Rouquette I; Souquet PJ; Audigier-Valette C; Sabourin JC; Decroisette C; Sakhri L; Brambilla E; McLeer-Florin A
Lung Cancer; 2014 Feb; 83(2):168-73. PubMed ID: 24380695
[TBL] [Abstract][Full Text] [Related]
3. ROS1 rearrangements in non-small cell lung cancer: screening by immunohistochemistry using proportion of cells staining without intensity and excluding cases with MAPK pathway drivers improves test performance.
Prall OWJ; Browning J; Nastevski V; Caporarello S; Bates B; Hewitt CA; Arenas A; Lamb G; Howlett K; Arnolda R; Adeloju R; Stuart S; Xu H; Fellowes A; Fox SB
Pathology; 2022 Apr; 54(3):279-285. PubMed ID: 34635319
[TBL] [Abstract][Full Text] [Related]
4. Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement.
Wu J; Lin Y; He X; Yang H; He P; Fu X; Li G; Gu X
BMC Cancer; 2016 Aug; 16():599. PubMed ID: 27488371
[TBL] [Abstract][Full Text] [Related]
5. Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target.
Selinger CI; Li BT; Pavlakis N; Links M; Gill AJ; Lee A; Clarke S; Tran TN; Lum T; Yip PY; Horvath L; Yu B; Kohonen-Corish MR; O'Toole SA; Cooper WA
Histopathology; 2017 Feb; 70(3):402-411. PubMed ID: 27599111
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Different
Dülger O; Öz B
Balkan Med J; 2023 Sep; 40(5):344-350. PubMed ID: 37318131
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of a new diagnostic immunohistochemistry approach for ROS1 rearrangement in non-small cell lung cancer.
Wang W; Cheng G; Zhang G; Song Z
Lung Cancer; 2020 Aug; 146():224-229. PubMed ID: 32580101
[TBL] [Abstract][Full Text] [Related]
8. Histologic and Molecular Characterization of Non-Small Cell Lung Carcinoma With Discordant ROS1 Immunohistochemistry and Fluorescence In Situ Hybridization.
Wilcock DM; Schmidt RL; Furtado LV; Matynia AP; Deftereos G; Sirohi D
Appl Immunohistochem Mol Morphol; 2022 Jan; 30(1):19-26. PubMed ID: 34534989
[TBL] [Abstract][Full Text] [Related]
9. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study.
Conde E; Hernandez S; Martinez R; Angulo B; De Castro J; Collazo-Lorduy A; Jimenez B; Muriel A; Mate JL; Moran T; Aranda I; Massuti B; Rojo F; Domine M; Sansano I; Garcia F; Felip E; Mancheño N; Juan O; Sanz J; Gonzalez-Larriba JL; Atienza-Cuevas L; Arriola-Arellano E; Abdulkader I; Garcia-Gonzalez J; Camacho C; Rodriguez-Abreu D; Teixido C; Reguart N; Gonzalez-Piñeiro A; Lazaro-Quintela M; Lozano MD; Gurpide A; Gomez-Roman J; Lopez-Brea M; Pijuan L; Salido M; Arriola E; Company A; Insa A; Esteban-Rodriguez I; Saiz M; Azkona E; Alvarez R; Artal A; Plaza ML; Aguiar D; Enguita AB; Benito A; Paz-Ares L; Garrido P; Lopez-Rios F
J Thorac Oncol; 2019 Dec; 14(12):2120-2132. PubMed ID: 31349061
[TBL] [Abstract][Full Text] [Related]
10. ROS1 rearrangements in lung adenocarcinomas are defined by diffuse strong immunohistochemical expression of ROS1.
Fielder T; Butler J; Tierney G; Holmes M; Lam KY; Satgunaseelan L; Colebatch AJ; Mahar A; Gupta R; O'Toole S; Cooper WA
Pathology; 2022 Jun; 54(4):399-403. PubMed ID: 34702583
[TBL] [Abstract][Full Text] [Related]
11. Detection of ROS1-positive non-small cell lung cancer on cytological specimens using immunocytochemistry.
Vlajnic T; Savic S; Barascud A; Baschiera B; Bihl M; Grilli B; Herzog M; Rebetez J; Bubendorf L
Cancer Cytopathol; 2018 Jun; 126(6):421-429. PubMed ID: 29451745
[TBL] [Abstract][Full Text] [Related]
12. ROS1 rearrangements define a unique molecular class of lung cancers.
Bergethon K; Shaw AT; Ou SH; Katayama R; Lovly CM; McDonald NT; Massion PP; Siwak-Tapp C; Gonzalez A; Fang R; Mark EJ; Batten JM; Chen H; Wilner KD; Kwak EL; Clark JW; Carbone DP; Ji H; Engelman JA; Mino-Kenudson M; Pao W; Iafrate AJ
J Clin Oncol; 2012 Mar; 30(8):863-70. PubMed ID: 22215748
[TBL] [Abstract][Full Text] [Related]
13. Testing for ROS1 in non-small cell lung cancer: a review with recommendations.
Bubendorf L; Büttner R; Al-Dayel F; Dietel M; Elmberger G; Kerr K; López-Ríos F; Marchetti A; Öz B; Pauwels P; Penault-Llorca F; Rossi G; Ryška A; Thunnissen E
Virchows Arch; 2016 Nov; 469(5):489-503. PubMed ID: 27535289
[TBL] [Abstract][Full Text] [Related]
14. Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer.
Pavlakis N; Cooper C; John T; Kao S; Klebe S; Lee CK; Leong T; Millward M; O'Byrne K; Russell PA; Solomon B; Cooper WA; Fox S
Pathology; 2019 Dec; 51(7):673-680. PubMed ID: 31668406
[TBL] [Abstract][Full Text] [Related]
15. Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer.
Lim SM; Chang H; Cha YJ; Liang S; Tai YC; Li G; Pestova E; Policht F; Perez T; Soo RA; Park WY; Kim HR; Shim HS; Cho BC
Lung Cancer; 2017 Sep; 111():79-83. PubMed ID: 28838404
[TBL] [Abstract][Full Text] [Related]
16. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion.
Rimkunas VM; Crosby KE; Li D; Hu Y; Kelly ME; Gu TL; Mack JS; Silver MR; Zhou X; Haack H
Clin Cancer Res; 2012 Aug; 18(16):4449-57. PubMed ID: 22661537
[TBL] [Abstract][Full Text] [Related]
17. ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas.
Sholl LM; Sun H; Butaney M; Zhang C; Lee C; Jänne PA; Rodig SJ
Am J Surg Pathol; 2013 Sep; 37(9):1441-9. PubMed ID: 23887156
[TBL] [Abstract][Full Text] [Related]
18. A Validation Study for the Use of ROS1 Immunohistochemical Staining in Screening for ROS1 Translocations in Lung Cancer.
Viola P; Maurya M; Croud J; Gazdova J; Suleman N; Lim E; Newsom-Davis T; Plowman N; Rice A; Montero MA; Gonzalez de Castro D; Popat S; Nicholson AG
J Thorac Oncol; 2016 Jul; 11(7):1029-39. PubMed ID: 27179848
[TBL] [Abstract][Full Text] [Related]
19. FISH patterns of ROS1, MET, and ALK with a correlation of ALK immunohistochemistry in lung cancer: a case for introducing ALK immunohistochemistry 'Equivocal' interpretation category in the Ventana anti-ALK (D5F3) CDx assay - A tertiary cancer center experience.
Singh A; Kumar R; Shetty O; Desai S; Rane S
Indian J Cancer; 2022; 59(1):18-25. PubMed ID: 33402590
[TBL] [Abstract][Full Text] [Related]
20. Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples.
Zito Marino F; Rossi G; Cozzolino I; Montella M; Micheli M; Bogina G; Munari E; Brunelli M; Franco R
J Clin Pathol; 2020 Feb; 73(2):96-101. PubMed ID: 31562206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
